Reuters logo
BRIEF-Five Prime Therapeutics, Bristol-Myers Squibb extend research term to discover immuno-oncology therapies
January 4, 2017 / 9:46 PM / 10 months ago

BRIEF-Five Prime Therapeutics, Bristol-Myers Squibb extend research term to discover immuno-oncology therapies

Jan 4 (Reuters) - Five Prime Therapeutics Inc

* Five Prime Therapeutics and Bristol-Myers Squibb extend research term in collaboration to discover novel immuno-oncology therapies for three immune checkpoint pathways

* Says Bristol-Myers Squibb has now elected to extend research term from its original ending date of March 2017 to march 2018

* Says Bristol-Myers Squibb will provide additional research funding for 12-month extension of research term Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below